A 15-year-old with obesity, type 2 diabetes, and high uric acid showed dramatic improvements across all metabolic markers after 36 weeks on the GLP-1/glucagon dual agonist Mazdutide, with no adverse events reported.
16.8 kg Lost in 36 WeeksA 15-year-old on dose-escalated Mazdutide also saw HbA1c drop 22%, uric acid fall 37%, triglycerides decrease 69%, and fatty liver completely resolve
What the researchers found
Over 36 weeks of dose-escalated Mazdutide (2 mg → 4 mg → 6 mg weekly subcutaneous injections) combined with metformin and insulin, this 15-year-old patient achieved: 16.8 kg weight loss (18.89% BMI reduction from 30.64 kg/m²), HbA1c reduction of 21.88% (from 9.60%), uric acid decrease of 37.00% (from 511 μmol/L), triglyceride reduction of 69.02%, total cholesterol decrease of 13.65%, LDL cholesterol decrease of 17.27%, and complete resolution of hepatic steatosis by week 14. No hypoglycemic episodes or adverse events occurred, and benefits were sustained after treatment.
Why it matters
Mazdutide is a next-generation dual-agonist peptide that targets both GLP-1 and glucagon receptors, potentially offering broader metabolic benefits than GLP-1-only drugs like semaglutide. This is one of the first reports of its use in an adolescent, and the comprehensive metabolic improvements — weight loss, blood sugar control, uric acid reduction, lipid improvement, and fatty liver reversal — suggest it could be particularly valuable for young patients with complex metabolic syndrome.
How the study worked
This is a single-patient case report. A 15-year-old male with BMI of 30.64 kg/m², HbA1c of 9.60%, and serum uric acid of 511 μmol/L received Mazdutide via subcutaneous injection once weekly, escalating from 2 mg to 4 mg to 6 mg, alongside metformin and insulin. Outcomes were tracked over 36 weeks with blood tests and liver ultrasound imaging.
What this study cannot tell us
This is a single case report, which cannot establish causality or generalizability. The patient received Mazdutide alongside metformin and insulin, making it impossible to isolate Mazdutide's individual contribution. No control group or comparison arm exists. Long-term safety in adolescents remains unknown. One patient's experience cannot predict population-level outcomes.
How to read the evidence
As a single case report, this represents the lowest tier of clinical evidence. While the results are striking, they reflect one patient's experience and cannot be generalized without larger controlled studies.
When this study was published
Published in 2025, this is one of the earliest case reports of Mazdutide use in an adolescent, reflecting the very beginning of clinical experience with this dual agonist in younger patients.
The bigger picture
The peptide therapeutics landscape for obesity and diabetes is expanding beyond single-target GLP-1 agonists. Dual and triple agonists like Mazdutide (GLP-1/glucagon) and tirzepatide (GLP-1/GIP) represent the next wave. This case report adds early evidence that dual agonism may deliver superior metabolic outcomes, and that these benefits extend to adolescents — a population with growing need and limited treatment options.
Questions still open
- How does Mazdutide's metabolic profile compare to semaglutide or tirzepatide in head-to-head adolescent studies?
- Will the metabolic benefits observed in this case persist long-term after treatment discontinuation?
- What is the mechanism behind Mazdutide's particularly strong effect on uric acid and triglyceride reduction?
Common questions
What is Mazdutide and how is it different from semaglutide?
Is Mazdutide approved for use in teenagers?
Read the original research
Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.
Frontiers in endocrinology, 16, 1654506
Citation
Cheng, Wenfei; Chen, Zilong; Li, Puyu; Zhang, Yingyu; Ma, Yujin; Liu, Peng; Jiang, Hongwei. (2025). Case Report: Efficacy and safety of dose-escalated Mazdutide, a GLP-1/GCGR dual agonist, in an adolescent with obesity, type 2 diabetes, and hyperuricemia.. Frontiers in endocrinology, 16, 1654506. https://doi.org/10.3389/fendo.2025.1654506